China Universal Asset Management Company’s ProQR Therapeutics PRQR Stock Holding History

China Universal Asset Management Company’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.3K	Sell	12,500 -7,500	-38%	-$12.3K	﹤0.01%	493
2026 Q1	$32.4K	Buy	+20,000	New	+$32.8K	﹤0.01%	478
2022 Q4	–	Sell	-701	Closed	-$1K	–	444
2022 Q3	$1K	Buy	+701	New	+$563	﹤0.01%	410

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

China Universal Asset Management Company's PRQR Position: Q2 2026 in Review

China Universal Asset Management Company reduced its ProQR Therapeutics (PRQR) stake by 38% in Q2 2026, selling an estimated $12.3K and leaving 12,500 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #493.

China Universal Asset Management Company first reported a position in PRQR in Q3 2022 and has held it in 3 quarters since. The position peaked at $32.4K in Q1 2026. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

China Universal Asset Management Company held 12,500 shares of ProQR Therapeutics worth $23.3K as of Q2 2026.
China Universal Asset Management Company sold 7,500 ProQR Therapeutics shares in Q2 2026, an estimated $12.3K.
ProQR Therapeutics made up ﹤0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #493 holding.
China Universal Asset Management Company first reported a position in ProQR Therapeutics in Q3 2022 and has held it in 3 quarters since.
China Universal Asset Management Company's ProQR Therapeutics position peaked at $32.4K in Q1 2026.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.